Predicting Immunotherapy Side Effects in Solid Tumors
Part of Cancer clinical trials.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a solid tumor cancer (a cancer that forms a lump or mass).
- You are about to receive your first-ever immunotherapy treatment (such as PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors) as part of your standard care.
- You have at least one tumor that can be measured on scans.
- You are being treated at a participating department of the AP-HM (Marseille public hospitals) and can follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.